Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
复制标题
DOI：
10.1176/appi.ajp.162.9.1744
复制
发表时间：
2005-09-01
影响因子：
17.7
通讯作者：
Perkins, DO
中科院分区：
文献类型：
--
作者：
Graham, KA;Gu, HB;Perkins, DO
目标：本研究旨在确定金刚烷胺是否影响服用奥氮平的精神病患者的体重增加。方法：21名服用奥氮平后体重增加至少5磅的成年人被随机分配接受金刚烷胺（N= 12）或安慰剂（N= 9）。服用奥氮平的时间范围为1至44个月。结果：服用金刚烷胺的受试者中体重增加的人数显著减少，金刚烷胺组体重指数的平均变化为-0.07 kg/m2，安慰剂组为1.24 kg/m2。当作者控制了基线体重指数和奥氮平治疗时间时，该效应仍然显著。空腹血糖、胰岛素、瘦素、催乳素和血脂水平无变化。阳性和阴性症状量表评分保持stabil.Conclusions：金刚烷胺诱导体重稳定的受试者服用奥氮平，耐受性良好。
Objective: This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine.Method: Twenty-one adults who had gained at least 5 lb with olanzapine were randomly assigned to receive amantadine (N= 12) or placebo ( N= 9) in addition to olanzapine. The length of time taking olanzapine ranged from 1 to 44 months. Body mass index, psychiatric status, and fasting blood levels were assessed at baseline and 12 weeks.Results: Significantly fewer subjects taking amantadine gained weight, with a mean change in body mass index of -0.07 kg/m(2) for the amantadine group and 1.24 kg/m(2) for the placebo group. This effect remained significant when the authors controlled for baseline body mass index and length of olanzapine treatment. No changes in fasting glucose, insulin, leptin, prolactin, and lipid levels were seen. Positive and Negative Syndrome Scale scores remained stable.Conclusions: Amantadine induced weight stabilization in subjects taking olanzapine and was well tolerated.